CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2024年8月25日～2024年8月31日の間に収集した論文情報を追加しました。

  1. Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system.

  免疫チェックポイント阻害剤とCMV感染の関連が確認された

  対象DB：FAERS

  2. Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS).

  非定型抗精神病薬の肝毒性は顕著ではない

  対象DB：FAERS

  3. An analysis of the safety of Sevoflurane drugs: A disproportionality analysis based on Food and Drug Administration Adverse Event Reporting System.

  セボフルランの副作用として心房細動を発見

  対象DB：FAERS

  4. Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.

  眼科用プロスタグランジン製剤の副作用シグナルを特定

  対象DB：FAERS

  5. Exploring the correlation between cardiovascular adverse events and antidepressant use: A retrospective pharmacovigilance analysis based on the FDA Adverse Event Reporting System database.

  抗うつ薬は心血管系の副作用と関連し、リスクの差がある

  対象DB：FAERS

  6. Association between age and onset of daptomycin-induced adverse events using the U.S. Food and Drug Administration Adverse Event Reporting System.

  ダプトマイシンは年齢により副作用リスクが異なる

  対象DB：FAERS

  7. Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents.

  口腔粘膜炎は女性や若年層に多く、キナーゼ阻害薬が誘発因子

  対象DB：FAERS

  8. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis.

  アダリムマブの小児使用における副作用は、注射部位の隆起や腸瘻が顕著

  対象DB：FAERS

  9. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.

  CAR T細胞製品による副作用の違いを比較し、特に神経系や心肺毒性に注目

  対象DB：FAERS

  10. Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.

  第3世代アロマターゼ阻害剤は、手指のけいれんや間質性肺疾患などの重篤な副作用を示す可能性

  対象DB：FAERS

  11. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study.

  CDK4/6阻害剤は心不全や高血圧などの心血管毒性と関連があり

  対象DB：FAERS,KAERS

  12. Co-Occurring Infections in Cancer Patients Treated with Checkpoint Inhibitors Significantly Increase the Risk of Immune-Related Adverse Events.

  免疫チェックポイント阻害剤は多様な免疫関連副作用を引き起こす可能性

  対象DB：FAERS

  13. Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature.

  アスパラギナーゼ製品は、肝静脈閉塞症（VOD）を引き起こす可能性

  対象DB：FAERS

  14. Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system.

  ルマテペロンの副作用には、予期せぬ症状や発症までの期間が含まれ、安全性情報が提供された

  対象DB：FAERS

  15. Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data.

  トラロキヌマブの副作用には、注射部位反応や新たなリスクが含まれ、安全性情報が提供された

  対象DB：FAERS

  16. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.

  サクビトリル/バルサルタンの副作用には低血圧や新たなリスクが含まれ、安全性の理解が進展

  対象DB：FAERS

  17. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example.

  セリュメチニブの副作用には新たなリスクがあり、PI3K/Akt経路やEGFR関連経路が関与

  対象DB：FAERS

  18. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database.

  インクリシランの副作用には筋肉痛、肝障害、糖尿病、神経認知障害が含まれる

  対象DB：FAERS

  19. Increased Pneumonia Risk Associated with Concomitant Use of Inhaled Corticosteroids and Benzodiazepines: A Pharmacovigilance Analysis.

  ICSとBZDの併用で肺炎リスクが増加する

  対象DB：FAERS

  20. A comprehensive assessment of the association between common drugs and psychiatric disorders using Mendelian randomization and real-world pharmacovigilance database.

  慢性疾患薬の長期的脳影響と精神疾患リスクを解析

  対象DB：FAERS

  21. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.

  低分子ヘパリンの副作用を全体および妊婦で分析し、新たなシグナルを発見

  対象DB：FAERS

  22. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.

  テプロツムマブの副作用分析で新たなシグナルを発見

  対象DB：FAERS

  23. Comparison of Adverse Events Following Immunosuppressant Administration for Pediatric Patients With Renal Transplants Categorized by Two-Year Age Increments Using the U.S. Food and Drug Administration Adverse Event Reporting System.

  小児腎移植患者の副作用は年齢によって異なる

  対象DB：FAERS

  24. Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study.

  糖尿病治療薬は運動障害のリスクを増加させる

  対象DB：FAERS

  25. Coagulation dysfunction events associated with echinocandins: a real-world study from FDA adverse event reporting system (FAERS) database.

  エキノカンジンは抗真菌薬の中で凝固障害のリスクが高い

  対象DB：FAERS

  26. Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis.

  tPA治療の副作用をFAERSで比較し、テネクテプラーゼが最も強いシグナルを示した

  対象DB：FAERS

  27. Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database.

  T-DM1の肝胆道系副作用のリスクがFAERSで確認された

  対象DB：FAERS,KAERS

  28. Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective.

  VigiBaseで薬剤による糸球体疾患を分析。新たな腎毒性薬を特定

  対象DB：VigiBase

  29. Disproportionality analysis of psychiatric morbidities associated with isotretinoin using VigiBase.

  イソトレチノインと精神障害の関連をVigiBaseで分析

  対象DB：VigiBase

  30. Comprehensive Analysis of Drug-Induced Parkinson-like Events.

  薬剤によるパーキンソン様症状のリスクとメカニズムを分析

  対象DB：JADER

  31. Association of Intensive Care Unit Case Volume With Mortality and Cost in Sepsis Based on a Japanese Nationwide Medical Claims Database Study.

  ICUの症例数が多いほど、敗血症患者の院内死亡率は低く、医療コストは高い

  対象DB：DPC

  32. Clinical research using real-world data: A narrative review.

  RCTとRWDの比較と、日本の保険データベース利用の重要性をレビュー

  対象DB：DPC,DeSC,NDB

  33. Effectiveness and Safety of Reduced and Standard Daily Doses of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: A Cohort Study Using National Database Representing the Japanese Population.

  日本の非弁膜症性心房細動患者で、DOACの減量と標準量の効果と安全性を比較

  対象DB：NDB

  34. Evaluation of the Correspondence between the Concentration of Antimicrobials Entering Sewage Treatment Plant Influent and the Predicted Concentration of Antimicrobials Using Annual Sales, Shipping, and Prescriptions Data.

  日本の下水処理場での抗菌薬濃度予測と実測値の一致を評価

  対象DB：NDB

  35. Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed.

  多くの喘息患者がSITTを迅速に開始している

  対象DB：MDV

  36. Association Between IV Contrast Media Exposure and Acute Kidney Injury in Patients Requiring Emergency Admission: A Nationwide Observational Study in Japan.

  造影CTはAKIリスク増加なしで入院死亡率に有益

  対象DB：MDV

  37. Time trends in the epidemiology of food allergy in England: an observational analysis of Clinical Practice Research Datalink data.

  英国での食物アレルギーが増加しており、主にプライマリケアで管理されている

  対象DB：CPRD

  38. Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021.

  慢性呼吸器疾患の診断と治療に遅れが見られる

  対象DB：CPRD

  39. An international study to investigate and optimise the safety of discontinuing valproate in young men and women with epilepsy: Protocol.

  バルプロ酸中止のリスクを評価し、安全な代替薬を提案

  対象DB：CPRD

  40. Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study.

  アピキサバンはワルファリンと同等で、特定の条件下では劣る可能性がある

  対象DB：CPRD

  41. Risk of unintended consequences from lower antibiotic prescribing for respiratory tract infections in primary care.

  抗生物質の処方削減は入院リスクを増加させない

  対象DB：CPRD

  42. Impact of moderate-to-high-suicide-intent in major depressive disorder: a retrospective cohort study on patient characteristics and healthcare resource utilisation in England.

  自殺意図のあるMDD患者は若く、医療利用が多い

  対象DB：CPRD

  43. The effect of comorbidities on diagnostic interval for lung cancer in England: a cohort study using electronic health record data.

  他疾患が肺がん診断の遅れを引き起こす

  対象DB：CPRD

  44. Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.

  SGLT2iの使用率は低く、特に高齢者で顕著

  対象DB：THIN

  45. Association between self-reported difficulty in chewing or swallowing and frailty in older adults: A retrospective cohort study.

  咀嚼困難は、誤嚥性肺炎や死亡リスクを増加させる

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み